Monte Rosa appoints former Momenta CSO Anthony Manning to Board

Monte Rosa Therapeutics, Inc.

Board expanded from 8 to 9 directors; Dr. Manning fills newly created vacancy, effective July 25, 2023.
He will serve as a Class II director until the 2026 annual meeting of stockholders.
Board determined Manning is independent under Nasdaq listing standards.
Manning was CSO at Momenta Pharma, which was acquired by J&J for $6.5B in 2020; expertise in autoimmune disease and drug discovery.
He will receive cash and equity compensation per the company's non-employee director policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anthony M. Manning

Director

GLUE · Monte Rosa Therapeutics, Inc.

Effective: 2023-07-25
Filed: July 26, 2023, 7:59 PM ET

the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony M. Manning was appointed as Director at Monte Rosa Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.

View on SEC.gov

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-034560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.